CA Patent

CA2538546C — Polymorphic forms of rifaximin, processes for their production and use thereof in medicinal preparations

Assigned to Alfasigma SpA · Expires 2011-04-19 · 15y expired

What this patent protects

Crystalline polymorphic forms of rifaximin (INN), referred to as rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form referred to as rifaximin .gamma., useful in the production of medicaments containing rifaximin for the oral and topical use and obtained by means…

USPTO Abstract

Crystalline polymorphic forms of rifaximin (INN), referred to as rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form referred to as rifaximin .gamma., useful in the production of medicaments containing rifaximin for the oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.

Drugs covered by this patent

Patent Metadata

Patent number
CA2538546C
Jurisdiction
CA
Classification
—
Expires
2011-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Alfasigma SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.